Boston Scientific Corporation

NYSE:BSX

Medical - Devices

Healthcare
$43.64 +1.00%

+$0.45 today

Market cap
$63.25B
Beta
0.56
P/E (TTM)
19.0
EPS (TTM)
$2.39
52W Low $44.44High $109.50

Volume 13.21M

Average 19.45M

BSX Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Boston Scientific CorporationNYSE: BSX

Short-term Debt · Q2 FY2026 · quarter ended Jun 2026

Short-term debt rises 256.0% from a year ago

Short-term debt stood at $1.71B at the end of Q2 FY2026, up 256.0% from a year earlier and up 4068.3% from the prior quarter. Over 3 fiscal years it compounded at +168.9% a year.

Context

  • Short-term debt amounted to 3.8% of total assets at the end of Q2 FY2026, up 2.6 pp from a year earlier.
  • Short-term debt increased in 2 of the last 3 fiscal years.

What to watch

Whether short-term debt keeps rising in the next quarterly balance sheet after a +256.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.71B+4068.3% QoQ
Last fiscal yearDec 2025
$389M-78.1% YoY
Year agoJun 2025
$480M+256.0% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+256.0%——
1 year-78.1%——
3-year CAGR+168.9%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
389M USD
Year-over-year change
-78.1%
4-year CAGR
+10.5%

Short-term Debt vs competitors

How BSX compares with its peers on the latest reported figures

  • BSX's Jun 2026 short-term debt of $1.71B is the 2nd highest of the 11 companies compared; the peer median is $355.5K.
  • Its year-over-year change of +256.0% is the highest of 6, against a peer median of -12.5%.
  • Short-term debt amounts to 3.8% of total assets for BSX, versus a peer median of 0.0%.
BSX Competitors Peer median
Short-term Debt for BSX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MDTMedtronic plcJul 2026$2.54B +4.4%+415.6%2.7%
BSXBoston Scientific CorporationJun 2026$1.71B +256.0%+168.9%3.8%
TFXTeleflex IncorporatedJun 2026$87.5M -12.5%+4.6%1.3%
MMSIMerit Medical Systems, Inc.Sep 2026$10.38M —-21.2%—
LIVNLivaNova PLCSep 2026$3.9M -95.4%+10.4%0.1%
CNMDCONMED CorporationMar 2026$711K -0.4%-78.3%0.0%
EWEdwards Lifesciences CorporationJun 2026$0 ——0.0%
PENPenumbra, Inc.Jun 2026$0 ——0.0%
ATRCAtriCure, Inc.Jun 2026$0 —-2.2%0.0%
ANGOAngioDynamics, Inc.Feb 2026$0 -100.0%-64.3%0.0%
CVRXCVRx, Inc.Mar 2026$0 ——0.0%
Peer median (excluding BSX) $355.5K-12.5%-2.2%0.0%

Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.93B928M865M414M2.05B
Short-term Investments00000
Net Receivables1.78B1.97B2.23B2.56B2.93B
Inventory1.61B1.87B2.48B2.81B2.94B
Other Current Assets799M731M622M831M580M
Total Current Assets6.32B5.76B6.51B6.92B8.79B
Property, Plant & Equipment (Net)2.69B2.83B3.3B3.74B4.5B
Goodwill11.99B12.92B14.39B17.09B18.28B
Intangible Assets6.12B5.9B6B6.68B7.02B
Long-term Investments412M407M413M555M842M
Tax Assets4.14B3.94B3.84B3.66B3.68B
Other Non-current Assets563M707M680M749M559M
Total Non-current Assets25.91B26.71B28.62B32.48B34.88B
Total Assets32.23B32.47B35.14B39.4B43.67B
Account Payables794M862M942M960M1.14B
Short-term Debt261M20M531M1.78B389M
Tax Payables209M232M220M307M299M
Deferred Revenue208M220M266M306M313M
Other Current Liabilities629M1.64B1.92B491M2.17B
Total Current Liabilities4.27B3.8B4.93B6.4B5.44B
Long-term Debt8.8B8.91B8.57B8.84B11.46B
Deferred Tax Liabilities310M144M134M155M220M
Deferred Revenue (Non-current)276M289M311M329M369M
Other Non-current Liabilities1.55B1.4B1.27B1.14B1.14B
Total Non-current Liabilities11.33B11.09B10.67B10.99B13.76B
Total Liabilities15.61B14.9B15.61B17.39B19.2B
Common Stock17M17M17M17M17M
Retained Earnings(1.39B)(750M)819M2.67B5.57B
Accumulated OCI263M269M49M275M(610M)
Other Stockholders Equity001M01M
Minority Interest00248M233M239M
Total Equity16.62B17.57B19.53B22B24.47B
Total Debt9.45B9.28B9.49B11.15B12.42B
Net Debt7.53B8.35B8.63B10.73B10.37B

Boston Scientific Corporation

NYSE:BSX

Intrinsic Alpha fair value

Locked

Current Price

$43.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.